Multibagger Selection: Grok 4.5's picks
Grok 4.5 picked VRDN, REPL, NRIX, AEVA, SERV with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | VRDN | — | 72% | — | — |
| 2 | REPL | — | 68% | — | — |
| 3 | NRIX | — | 70% | — | — |
| 4 | AEVA | — | 65% | — | — |
| 5 | SERV | — | 60% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +0.02% | +0.69% | 1.15x | 0 |
| 1 month | -12.35% | -11.60% | 1.15x | 0 |
The model's market view
Small- and mid-cap growth stocks face elevated rates and oil-driven inflation pressure that compresses multiples, yet biotech commercial launches, robotics fleet scaling, and LiDAR/AI-infrastructure design wins create asymmetric upside where operating inflection and specific 12-month catalysts can re-rate valuations sharply relative to the broader market.
Why each pick
VRDN
Newly commercial TED franchise (Lumvoa/veligrotug approved June 2026) plus subcutaneous autoinjector BLA planned Q1 2027 and FcRn pipeline data in 2H 2026 create a multi-product revenue ramp from a base of early launch sales; strong cash position supports execution without near-term dilution.
REPL
FDA accelerated approval of Tudriqev (RP1 + nivolumab) for advanced melanoma in August 2026 after prior rejections creates first commercial product; launch within ~60 days and confirmatory trial underway provide a clear 12-month revenue inflection from a zero base.
NRIX
Landmark Roche collaboration ($700M upfront, up to $2.3B total) for bexobrutideg (BTK degrader) validates platform, extends runway, and funds late-stage trials; multiple Phase 3 and expansion catalysts in CLL, CSU and MS within 12 months.
AEVA
4D LiDAR design wins converting toward production plus new Optical Connectivity business targeting AI data-center hyperscalers create dual growth vectors; 2026 revenue guidance of $30-36M implies 70-100% growth from 2025 base.
SERV
Autonomous sidewalk delivery fleet scaling with new Grubhub partnership and geographic expansion creates high-revenue-growth potential from a low base; hospital robot (Diligent) adds diversification; low absolute market cap amplifies percentage upside if utilization and robot economics improve.
Other models on the same run
| Model | Picks |
|---|---|
| GPT-5.6 Sol | LUNR, RCAT, POET, ONDS, AEVA |
| Claude Opus 5 | ICHR, OUST, RUM, USAR, EMAT |
| Muse Spark 1.1 | KPLT, INDP, BNC, CHPT, SWVL |
| Gemini 1.5 Pro | RCAT, LUNR, RDW, SMR, ENVX |
| DeepSeek | INOD, UMAC, CAPR, NUAI, PDYN |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.